TABLE 3.
Seasonal prevalence of short- and long-term relapses in three treatment groups
| Treatment | No. (%) of cases
|
||||
|---|---|---|---|---|---|
| Total | Nonrelapse | Relapse | Relapse period of:
|
||
| <6 mo (short term) | >6 mo, <12 mo (long term) | ||||
| First half (January to June) | |||||
| Bulaquine (a) | 40 | 24 | 16 | 13 (32.5) | 3 (7.5) |
| Primaquine (b) | 46 | 35 | 11 | 11 (23.91) | 0 (0.00) |
| Combined (a + b) | 86 | 59 | 27 | 24 (27.91) | 3 (3.49) |
| Placebo | 49 | 31 | 18 | 16 (32.65) | 2 (4.08) |
| Second half (July to December) | |||||
| Bulaquine (a) | 179 | 130 | 49 | 21 (11.73) | 28 (15.64) |
| Primaquine (b) | 174 | 126 | 48 | 25 (14.37) | 23 (13.22) |
| Combined (a + b) | 353 | 256 | 97 | 45 (12.75) | 52 (14.73) |
| Placebo | 175 | 103 | 72 | 26 (14.86) | 46 (26.29) |